May 24, 2024

Acute Bacterial Skin and Skin Structure Infections Market Driven by Increasing Antibiotic Resistance

The acute bacterial skin and skin structure infections (ABSSSI) market comprises topical and IV administered drugs for treating skin infections caused by bacteria. These infections include those affecting skin and deeper subcutaneous tissues, generally caused by Staphylococcus aureus and Streptococcus pyogenes bacteria. ABSSSIs range from minor infected abscesses and wounds to severe and life-threatening conditions. Antibiotics are the standard treatment for ABSSSIs and include cephalosporins, lipoglycopeptides, oxazolidinones, and glycylcyclines. However, antimicrobial resistance is on the rise, which is driving the need for new antibiotics and alternative treatments.

The global acute bacterial skin and skin structure infections market size is estimated to be valued at US$ 3,466.6 million in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period from 2023 to 2030.

Increasing cases of antibiotic-resistant microbial infections and a lack of new antibiotic drug approvals are fueling demand for ABSSSI treatments. Hospital-acquired ABSSSIs also continue to impose high healthcare costs.

Key Takeaways
Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.

The rising incidence of antibiotic-resistant microbial strains is driving the demand for new treatment alternatives. ABSSSIs caused by methicillin-resistant Staphylococcus aureus are increasingly common worldwide.

Major players are focusing on geographic expansion and new product development through mergers and acquisitions to capitalize on the high unmet need. Partnerships with governments and non-profit organizations are also being formed to boost antibiotic R&D.

Market Key Trends
One of the key trends in the acute bacterial skin and skin structure infections market is the growing pipeline of novel antibiotics candidates. Several pharmaceutical companies and biotechs are developing new classes of antibiotics such as pleuromutilins, glycylcyclines, and oxazolidinones to effectively treat resistant ABSSSIs. Some late-stage pipeline candidates include omadacycline, eravacycline, and iclaprim. Successful approvals of these drugs over the coming years could reshape treatment patterns and competition in the market.

Porter’s Analysis

Threat of new entrants: Low as it requires high investments and resources to establish an ABSSTI drugs manufacturing facility. The industry already has well established players.

Bargaining power of buyers: Moderate as there are a reasonable number of players offering treatment options. However patents provide pricing power to few drug makers.

Bargaining power of suppliers: Low due to fragmented nature of suppliers and their dependency on major drug makers for volume sales.

Threat of new substitutes: Low as there is limited availability of substitute treatments of ABSSTI. Most current treatment relies on antibiotics.

Competitive rivalry: High amongst existing players to capture more market share. Companies compete on the basis of patent exclusivity, marketing campaigns and portfolio expansion.

Geographical Regions:

North America accounts for the largest share of the ABSSTI market primarily due to high incidence of skin infections, presence of sophisticated healthcare infrastructure and reimbursement coverage.

Asia Pacific region is expected to grow at the fastest pace during the forecast period owing to increasing awareness, surge in healthcare spending and expanding base of generic drug manufacturers in the region.

Geographical Regions:

The United States represents the major market for ABSSTI drugs globally accounting for over 40% share, led by high incidence of such infections and reliable reimbursement policies.

China market is poised to expand considerably and emerge as the second largest regional market by 2030 on back of vast population base, improving access to healthcare and focus of international players on tapping opportunities in the country.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it